Loading…

Natera, Inc.NTRACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Runs genetic testing—prenatal screening, cancer monitoring and organ-transplant rejection tests—via proprietary molecular diagnostics.

Momentum neutral 56
Mkt cap
$42.0B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$805M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-32.8 pp
WACC 12.8%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$289.50
1D+0.7%
1W-9.5%
1M-28.7%
3M-10.9%
6M+41.3%
YTD+26.4%
1Y+40.5%
ATR %7.4%
Beta1.35
52w lowhigh33.8% off high

What Natera does

Runs genetic testing—prenatal screening, cancer monitoring and organ-transplant rejection tests—via proprietary molecular diagnostics.

Earns per test: it runs samples in its own labs and bills insurers and Medicare and, for some tests, patients. How much it collects depends on coverage and reimbursement decisions as much as test volume. Prenatal screening is the older base; Signatera, a cancer-recurrence test tailored to each patient's tumour, is the growth engine.

Products and services

  • Panorama (prenatal screening)
  • Signatera (cancer minimal residual disease)
  • Prospera (organ transplant rejection)

Customers

  • OB-GYNs and expecting parents
  • Oncologists
  • Transplant physicians

Where it sits in the supply chain

  • Healthcare
  • Diagnostics/genetic testing
  • Molecular diagnostic testing services

What could go right

  • Signatera oncology test adoption and payer coverage
  • Volume growth across all test lines

What could go wrong

  • Reimbursement/payer coverage risk
  • Competitive pricing pressure in liquid biopsy

Moat: narrow (IP / patents, data, process know-how). Proprietary personalized-assay technology (Signatera) and a large clinical-evidence base create switching costs.

Headquarters: Austin, Texas, US · Founded: 2004 · Employees: 6,140

Named competitors

Natera at a glance

Size Natera (NTRA) is a United States Health Care company (Biotechnology) with a market value of $42.0B, the 287th largest of 3,085 United States companies the cockpit tracks. Shares closed at $289.50 on 18 Nov 2026.

Performance Over six months the shares gained 41.3%, against +25.2% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 19 in its peer set.

Growth Revenue grew 37.4% over the last twelve months (peer median +13.9%); the operating margin is -8.8% (peer median 25.1%).

Valuation It trades at 14.1× enterprise value to sales against a peer median of 7.2× (4th most expensive of 19).

Capital Return on invested capital runs 32.8 points below its cost of capital (12.8% WACC).

Short interest Short interest is 4.2% of the free float (30 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026NTRA 142Peer median 120
Six months, rebased to 100: Natera against the median of its 18 peers (local-currency closes).

Natera financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.91B$2.31B$1.70B$1.08B$820M
Revenue growth—+36%+57%+32%—
Gross profit$1.88B$1.49B$1.02B$493M$364M
EBITDA-$179M-$263M-$191M-$405M-$501M
Net income-$165M-$208M-$190M-$435M-$548M
Free cash flow$52.5M$109M$69.2M-$286M-$479M
Capital expenditure$181M$139M$76.9M$39.2M$47.7M
Total debt$239M$214M$187M$442M$446M

Quarterly statements and history in the cockpit →

Natera competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%-20%0%+20%IQV207940068270LONNGMABARGXCSL2269MRNABNTXNBIXELAN1093HALONTRA6-month return →1-month return →
Up and to the right = strong over both horizons. Natera is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×10×20×30×IQV207940068270LONNGMABARGXCSL2269MRNABNTXNBIXBBIOELANHALONTRARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Natera is the large dot.

Natera competitors and peer comparison

Head to head with its named competitors (NTRA vs ILMN vs GH vs MYGN)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Natera NTRA$42.0B+41%+37%-9%14.1×n/a
Illumina ILMN$31.8B+48%+6%21%7.2×27.2%
Guardant Health GH$19.6B+26%+42%-39%15.9×n/a
Myriad Genetics MYGN$530M+45%-3%-13%0.8×n/a

How Natera compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Natera against its 18 peers (data as of 18 Nov 2026)
MeasureNTRAPeer medianRank in peer set
1-month return-28.7%+2.9%lowest of 19
6-month return+41.3%+25.2%6th highest of 19
Distance from 52-week high-33.8%-12.8%lowest of 19
Revenue growth (TTM)+37.4%+13.9%6th highest of 19
Operating margin-8.8%25.1%4th lowest of 19
EV / Sales14.1×7.2×4th most expensive of 19
ROIC minus cost of capital-32.8 pp+2.2 pp4th lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Natera NTRAUnited States$42.0B+41%+37%-9%14.1×n/an/a
Iqvia IQVUnited States$42.5B+50%+9%14%3.3×16.8%+7.5%
Samsung Biologics 207940.KSSouth Korea$48.7B-6%-20%43%14.5×7.0%+31.4%
Celltrion 068270.KSSouth Korea$34.9B+12%+40%32%9.0×10.6%+17.6%
Lonza LONN.SWSwitzerland$53.9B+36%-11%25%7.8×15.6%+7.7%
Genmab A/S GMAB.CODenmark$30.8B+103%+15%31%8.4×11.6%+19.5%
argenx SE Sponsored ADR ARGXUnited States$59.1B+17%+71%29%10.3×11.7%+151.4%
CSL CSL.AXAustralia$63.7B+102%-2%26%4.8×6.8%+11.0%
United Therapeutics UTHRUnited States$24.6B+2%+2%44%7.1×0.3%+16.5%
Wuxi Bio 2269.HKHong Kong$23.1B+35%+22%32%6.7×20.8%+30.2%
Moderna MRNAUnited States$79.6B+309%+13%-116%31.2×n/an/a
BioNTech SE Sponsored ADR BNTXUnited States$20.6B-8%-21%-61%1.9×n/an/a
Neurocrine Biosciences NBIXUnited States$16.5B+5%+38%25%4.4×-1.5%+22.3%
BridgeBio Pharma BBIOUnited States$15.2B+14%+167%-37%19.1×n/an/a
Elanco Animal Health ELANUnited States$13.3B+28%+12%8%3.2×32.9%+7.6%
Cspc Pharma 1093.HKHong Kong$12.0B+10%+25%28%2.1×-10.7%+0.1%
BioMarin Pharmaceutical BMRNUnited States$11.9B+22%+20%19%4.2×8.2%+12.0%
Bio-Techne TECHUnited States$11.4B+56%+1%21%9.2×31.6%+5.5%
Halozyme Therapeutics HALOUnited States$10.9B+39%+45%57%7.3×-0.3%+39.2%

Questions

Who are Natera's main competitors?
Named competitors: Illumina (GRAIL) (ILMN), Guardant Health (GH), Exact Sciences (private or unlisted), Myriad Genetics (MYGN). The cockpit's measured peer set (industry) also includes Iqvia (IQV), Samsung Biologics (207940.KS), Celltrion (068270.KS), Lonza (LONN.SW), Genmab A/S (GMAB.CO), argenx SE Sponsored ADR (ARGX).
Is Natera expensive compared with its peers?
On ev / sales it trades at 14.1× against a peer median of 7.2×, 4th most expensive of 19 in its peer set.
How has Natera stock performed?
Over six months to 18 Nov 2026 the shares returned +41.3% against +25.2% for the median peer; over one year +40.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.